From TokenPost · · 30s
Rhythm Pharmaceuticals Shares Rise 5.4%
Rhythm Pharmaceuticals shares climb 5.4% as Eli Lilly evaluates obesity market acquisition target.
In brief
Rhythm Pharmaceuticals shares climb 5.4% as Eli Lilly evaluates obesity market acquisition target. Rhythm Pharmaceuticals shares rose 5.4% at 12:22 p.m. ET on November 17 after Eli Lilly reportedly considered acquiring the company for obesity market expansion. Originally reported by TokenPost.
Rhythm Pharmaceuticals Shares

Rhythm Pharmaceuticals shares rose 5.4% at 12:22 p.m. ET on November 17.
Eli Lilly Evaluation
Eli Lilly reportedly evaluating Rhythm Pharmaceuticals as potential obesity market acquisition target.
Viking Therapeutics Speculation
Viking Therapeutics also part of obesity market acquisition speculation.
The takeaway
Rhythm Pharmaceuticals shares rose 5.4% at 12:22 p.m. ET on November 17 after Eli Lilly reportedly considered acquiring the company for obesity market expansion.
Read the TL;DR — this story on one card.





